National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

Statutory Rules

1979 No. 51

REGULATIONS UNDER THE NATIONAL HEALTH ACT 19531

WHEREAS it is provided by sub-section 101 (4) of the National Health Act 1953 that a drug or medicinal preparation that was not a pharmaceutical benefit under that Act immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS that Committee has recommended to the Minister that the following drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953, namely the drugs and medicinal preparations specified in Schedule 3 to the National Health (Pharmaceutical Benefits) Regulations, as amended by the following Regulations, that had not previously been prescribed as pharmaceutical benefits:

 NOW THEREFORE I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.

 Dated this twenty-ninth day of March 1979.

 ZELMAN COWEN

 Governor-General

 By His Excellency’s Command,

RALPH J. HUNT

Minister of State for Health

_______________

AMENDMENTS OF THE NATIONAL HEALTH

PHARMACEUTICAL BENEFITS) REGULATIONS2

1Commencement

 These Regulations shall come into operation on 1 April 1979.

2Schedule 1

 Schedule 1 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 1.

3Schedule 2

 Schedule 2 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 2.

4Schedule 3

 Schedule 3 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 3.

5Schedule 4

 Schedule 4 to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting items 18 and 22.

6Schedule 5

 Schedule 5 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 4.

_______________

SCHEDULE 1

Regulation 2

AMENDMENTS OF SCHEDULE 1 TO THE

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

• 1.

  Omit item 7.

• 2.

  After item 268 insert the following item:

 “268A Gelatin”.

• 3.

  After item 367 insert the following item:

 “367A Magnesium Sulphate Dried”.

• 4.

  After item 415 insert the following item:

 “415A Methylprednisolone Acetate”.

• 5.

  After item 416 insert the following item:

 “416A Methyltestosterone”.

• 6.

  After item 467 insert the following item:

 “467A Oxytetracycline Dihydrate”.

• 7.

  Omit item 507.

• 8.

  Omit item 575.

• 9.

  After item 577 insert the following item:

 “577A Quinalbarbitone Sodium”.

_______________

SCHEDULE 2

Regulation 3

AMENDMENTS OF SCHEDULE 2 OF THE

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

• 1.

  Omit item 7.

• 2.

  After item 28 insert the following items:

“28A

Benzyl Benzoate, B.P..............  –”.

 “28B Benzyl Benzoate Application,

 B.P..............................................  –”.

• 3.

  After item 65 insert the following item:

“65A

‘DE-LACT INFANT’.............  –”.

• 4.

  After item 84 insert the following item:

“84A

Econazole Nitrate.....................  –”.

• 5.

  Omit item 90, substitute the following item:

“90

Ethinyloestradiol...................... Ethynodiol Diacetate with

 Ethinyloestradiol

 Levonorgestrel with Ethinyloestradiol

 Lynoestrenol with Ethinyloestradiol

 Norethisterone with Ethinyloestradiol

 Norethisterone Acetate with

 Ethinyloestradiol

 Norgestrel with Ethinyloestradiol”.

• 6.

  After item 122 insert the following item:

“122A

Isoprenaline Sulphate, B.P. –”.

• 7.

  After item 125 insert the following item:

“125A

Levonorgestrel.......................... Levonorgestrel with Ethinyloestradiol”.

• 8.

  Omit item 138.

• 9.

  Omit item 155, substitute the following item:

“155

Nystatin..................................... Gramicidin with Neomycin Sulphate,

 Triamcinolone Acetonide and Nystatin Tetracycline,

 B.P.C., with a buffering agent and

 Nystatin Tetracycline Hydrochloride with Nystatin”.

• 10.

  Omit item 157.

• 11.

  After item 188 insert the following item:

“188A

Pyrimethamine, B.P................. Pyrimethamine, B.P., with Sulfadoxine”.

• 12.

  After item 197 insert the following item:

“197A

Sulfadoxine............................... Pyrimethamine, B.P., with Sulfadoxine”.

_______________

 SCHEDULE 3  Regulation 4

AMENDMENTS OF SCHEDULE 3 TO THE

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

• 1.

  Omit item 12.

• 2.

  Omit item 81.

• 3.

  After item 103 insert the following item:

“103A

‘DE-LACT INFANT’ ”.

• 4.

  After item 120 insert the following item:

“ 120A  Econazole Nitrate”.

• 5.

  Omit item 122.

• 6.

  Omit item 153, substitute the following item:

“153

Hamamelis Ointment, B.P.C.”.

• 7.

  After item 190 insert the following item:

“190A

Levonorgestrel”.

• 8.

  After item 194 insert the following item:

“194A

Mafenide Acetate”.

• 9.

  Omit item 198.

• 10.

  After item 217 insert the following item:

“217A

Naproxen”.

• 11.

  After item 237 insert the following item:

“237A

Perhexiline Maleate”.

• 12.

  After item 254 insert the following item:

“254A

Polyestradiol Phosphate”.

• 13

  Omit item 256.

• 14.

  After item 258 insert the following item:

“258A

Potassium Bicarbonate Effervescent Tablets”.

• 15.

  After item 259 insert the following item:

“259A

Potassium Chloride with Potassium Bicarbonate Effervescent Tablets”.

• 16.

  Omit item 260.

• 17.

  After item 314 insert the following item:

“314A

Sulfadoxine”.

_______________

 SCHEDULE 4  Regulation 6

AMENDMENTS OF SCHEDULE 5 TO THE

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

• 1.

  Omit item 4.

• 2.

  Omit item 5.

• 3.

  Omit item 41, substitute the following item:

“41

Cimetidine................................. With the written authority of the Permanent Head–

 Duodenal ulcer, confirmed by radiology, endoscopy or surgery Gastric ulcer, confirmed by radiology, endoscopy or surgery Zollinger-Ellison syndrome, proven by investigation”.

• 4.

  After item 53 insert the following item:

  • “53A

    1%, infant’................................ With the written authority of the Permanent Head, lactose intolerance in infants under the age of 6 months”.

• 5.

  After item 67 insert the following item:

“67A

Econazole Nitrate Cream....... Cutaneous candidiasis

 1%, 20 g Dermatomycosis

 Pityriasis versicolor”.

• 6.

  Omit item 77, substitute the following item:

  • “77

    Gentamicin Injection, B.P...... Any disease or condition in a patient receiving treatment in or at an approved hospital

   With the written authority of the Permanent Head–

   Endophthalmitis

   Infections where positive bacteriological evidence confirms that gentamicin sulphate is the most appropriate antibiotic

   Septicaemia including suspected septicaemia”.

• 7.

  After item 90 insert the following item:

“90A

Influenza Vaccine For prophylaxis of–

 (Monovalent) Pensioners who have not attained the age of 25 years

 Persons who have not attained the age of 25 years and who   are suffering from any severe debilitating disease, chronic   heart disease or chronic pulmonary disease”.

• 8.

  Omit item 91, substitute the following item:

“91

Influenza Vaccine For prophylaxis of–

 (Trivalent) Pensioners

 Persons suffering from any severe debilitating disease, chronic heart disease or chronic pulmonary disease”.

• 9.

  Omit item 102, Federal Digest following item:

“102

Mafenide Acetate With the written authority of the Permanent Head, treatment, in a   hospital, of burns”.

• 10.

  Omit item 107, substitute the following item:

“107

(1) Metformin Maturity onset diabetes not satisfactorily controlled by diet and

 Hydrochloride, B.P. other drugs, where the risk of lactic acidosis is minimised by

 (2) Metformin Tablets, B.P. excluding predisposing factors, especially reduced renal, hepatic

 or cardiovascular function”.

• 11.

  Omit item 113, substitute the following item:

“113

Methylprednisolone For local intra-articular or peri-articular infiltration”.

 Acetate Injection, B. P.

• 12.

  Omit item 114.

• 13.

  Omit item 116, substitute the following item:

“116

Methyltestosterone Carcinoma of the breast

 Tablets, B.P., 25 mg  Hypogonadism

 or 50 mg Klinefelter's syndrome (seminiferous tubule dysgenesis)”.

• 14.

  After item 139 insert the following item:

“139A

Perhexiline Maleate With the written authority of the Permanent Head, intractable

 angina not responding to other therapy”.

• 15.

  After item 142 insert the following item:

“142A

Phenoxybenzamine With the written authority of the Permanent Head–

 Capsules, B.P. Neurogenic urinary retention

 Phaeochromocytoma”.

• 16.

  After item 146 insert the following item:

“146A

Polyestradiol Phosphate......... Carcinoma of the breast

 Carcinoma of the prostate”.

• 17.

  Omit item 148.

• 18.

  After item 149 insert the following item:

“149A

Potassium Bicarbonate With the written authority of the Permanent Head, potassium

 Effervescent Tablets deficiency in patients with renal tubular acidosis”.

• 19.

  Omit item 185, substitute the following item:

“185

Triglycerides Oil, With the written authority of the Permanent Head–

 Medium Chain  Abetalipoproteinaemia, acanthocytosis

 Intestinal lymphangiectasia

 Patients requiring a ketogenic diet for intractable childhood   epilepsy”.

 

NOTES

1. Notified in the Commonwealth of Australia Gazette on 30 March 1979.

2. Statutory Rules 1960 No. 17 as amended by Statutory Rules 1960 Nos. 90 and 102; 1961 Nos. 59 and 137; 1962 Nos. 34, 101 and 114; 1963 Nos. 34, 69 and 107; 1964 Nos. 12, 57 and 135; 1965 Nos. 51, 151 and 152; 1966 Nos. 80 and 144; 1967 Nos. 67, 116 and 158; 1968 Nos. 44, 76, 88 and 146; 1969 Nos. 44, 107 and 185; 1970 Nos. 39, 94, 119 and 186; 1971 Nos. 44, 101, 136 and 154; 1972 Nos. 32, 121 and 205; 1973 Nos. 15, 57, 139 and 229; 1974 Nos. 37, 126 and 222; 1975 Nos. 50, 148 and 209; 1976 Nos. 84, 150, 195 and 255; 1977 Nos. 39, 125 and 221; and 1978 Nos. 47, 142, 153 and 245.